S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$12.83
+0.13 (+1.02%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.60
$13.21
50-Day Range
$9.92
$15.52
52-Week Range
$5.05
$17.22
Volume
2.19 million shs
Average Volume
5.44 million shs
Market Capitalization
$1.32 billion
P/E Ratio
25.16
Dividend Yield
N/A
Price Target
$14.81

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
15.5% Upside
$14.81 Price Target
Short Interest
Healthy
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.79
Upright™ Environmental Score
News Sentiment
1.11mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$11.43 M Sold Last Quarter
Proj. Earnings Growth
21.43%
From $0.70 to $0.85 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

86th out of 1,093 stocks

Pharmaceutical Preparations Industry

29th out of 547 stocks

CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

CPRX Catalyst Pharmaceuticals, Inc.
3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock
Why Catalyst Pharmaceuticals Shares Are Moving Today
Catalyst Pharmaceuticals: All Time High
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2021
Today
10/01/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$14.81
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$8.75
Forecasted Upside/Downside
+15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$39.48 million
Pretax Margin
42.58%

Debt

Sales & Book Value

Annual Sales
$140.83 million
Cash Flow
$0.39 per share
Book Value
$2.01 per share

Miscellaneous

Free Float
88,322,000
Market Cap
$1.32 billion
Optionable
Optionable
Beta
1.31

Social Links


Key Executives

  • Mr. Patrick J. McEnanyMr. Patrick J. McEnany (Age 75)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.05M
  • Ms. Alicia Grande C.M.A.Ms. Alicia Grande C.M.A. (Age 51)
    CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
    Comp: $617.94k
  • Dr. Steven R. MillerDr. Steven R. Miller (Age 60)
    COO & Chief Scientific Officer
    Comp: $745.71k
  • Dr. Gary Ingenito M.D.Dr. Gary Ingenito M.D. (Age 66)
    Ph.D., Chief Medical & Regulatory Officer
    Comp: $706.86k
  • Dr. Preethi Sundaram Ph.D. (Age 46)
    Chief Strategy Officer
    Comp: $511.25k
  • Ms. Mary Coleman
    VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D. (Age 58)
    Chief Compliance Officer & Chief Legal Officer
  • Mr. Pete Curry Sr.
    VP of Sales
  • Mr. Jeffrey Del Carmen (Age 51)
    Chief Commercial Officer
  • Mr. Philip B. Schwartz (Age 67)
    Corp. Sec.













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2022?

4 brokerages have issued 1-year price targets for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $8.75 to $18.00. On average, they expect the company's share price to reach $14.81 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2022?

Catalyst Pharmaceuticals' stock was trading at $6.77 on January 1st, 2022. Since then, CPRX shares have increased by 89.5% and is now trading at $12.83.
View the best growth stocks for 2022 here
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 25.15% and a net margin of 31.97%. During the same quarter in the previous year, the business posted $0.11 EPS.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $195.00 million-$205.00 million, compared to the consensus revenue estimate of $200.85 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $12.83.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.32 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.51 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.